60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6

Loading news article.

60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6 | WAPE

60 Degrees Pharmaceuticals Announces Enrollment Of Minimum 24 Patients Triggering Interim Analysis In Severe Babesiosis Tafenoquine Study, Results By October 6

Article summary

Related companies

Comments —